The weight of the evidence leads to the conclusion that enhanced genetic instability from a transgene or from common sequences in two or more transgenes is unlikely. Even then, the probability that any genetic instability will lead to an altered protein or metabolic product that creates a biosafety issue is exceedingly small; the production of a GE stack does not measurably increase this probability. There is no readily identifiable biological reason why genomic changes occurring in the breeding of a GE stack would be different in nature, scale, or frequency from those taking place in non-GE crops or in GE crops with a single event. Silencing of transgenes caused by duplicate sequences is only of primary concern to commercial companies because the added value from the GE trait would be lost, but it poses no biologically realistic hazard otherwise. Therefore, evaluating transgenic insertion stability in a GE stack does not provide information that can contribute to its safety assessment.